Recent investigations have focused on the overlap of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopamine neurotransmission. While GLP agonists are increasingly employed for addressing type 2 diabetes, their potential consequences on motivation circuits, specifically mediated by dopamine pathways, are receiving substantial i